

IMPROVING PATIENT MANAGEMENT

in von Willebrand Disease

An educational symposium initiated, organised and funded by Takeda.

Chaired by
Andreas Tiede

Wednesday, 7 February 2024
11:45–13:00 CET

| Time (CET) | Title | Speaker |
|-------------|---|---|
| 11:45–11:50 | Welcome and introduction | Andreas Tiede Hannover Medical School, Hannover, Germany |
| 11:50–12:10 | Diagnosis of von Willebrand disease: genetic considerations and subtypes | David Lillicrap Queen's University, Kingston, Canada |
| 12:10–12:30 | Long-term outcomes for patients with Type 3 von Willebrand disease | Flora Peyvandi University of Milan, Milan, Italy |
| 12:30–12:50 | Treatment decisions and long-term management of patients, including considerations for prophylaxis | Andreas Tiede Hannover Medical School, Hannover, Germany |
| 12:50–13:00 | Panel discussion | All (facilitated by Andreas Tiede) |

This symposium was initiated, organised and funded by Takeda Pharmaceuticals International AG.

© 2023. Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda logo are registered trademarks of Takeda Pharmaceutical Company Limited.

VV-MEDMAT-89366 12/2023

